glp 1 alcoholism A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity GLP‐1 Receptor Agonists for Treating

Certain foods trigger the same appetite-suppressing signals as GLP-1 medications by activating your body's natural satiety hormones

In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)

Learn how this impacts injury risk, recovery, and long-term function.

Novo and Lilly are using their direct-to-consumer online pharmacies to improve adherence, giving them clearer insight into why patients dont fill or refill prescriptions to offer targeted support

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

The primary outcome was change in HbA1c from randomisation to the end of treatment, secondary outcomes included body weight change